Head-To-Head Contrast: DarioHealth (DRIO) versus Its Rivals

DarioHealth (NASDAQ:DRIO) is one of 93 public companies in the “Healthcare Technology” industry, but how does it weigh in compared to its rivals? We will compare DarioHealth to similar businesses based on the strength of its valuation, profitability, earnings, analyst recommendations, institutional ownership, dividends and risk.

Profitability

This table compares DarioHealth and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-169.87%	-54.81%	-33.36%
DarioHealth Competitors	-762.90%	-30.85%	-15.65%

Insider & Institutional Ownership

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares DarioHealth and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
DarioHealth	$22.36 million	-$41.71 million	-0.39
DarioHealth Competitors	$346.01 million	-$24.15 million	12.96

DarioHealth’s rivals have higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations for DarioHealth and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1	1	3	0	2.40
DarioHealth Competitors	451	1532	2742	89	2.51

DarioHealth currently has a consensus price target of $9.00, suggesting a potential upside of 278.15%. As a group, “Healthcare Technology” companies have a potential upside of 45.15%. Given DarioHealth’s higher probable upside, equities research analysts plainly believe DarioHealth is more favorable than its rivals.

Risk & Volatility

DarioHealth has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, DarioHealth’s rivals have a beta of 1.11, indicating that their average stock price is 11% more volatile than the S&P 500.

Summary

DarioHealth rivals beat DarioHealth on 9 of the 13 factors compared.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.